Rachel Ambler

Rachel Ambler

Auto-generated profile, based on publicly available information

Rachel Ambler

School of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Science Advances
Verified
Journal Article
Open access
EMEdurne Mugarza
Edurne Mugarza
FMFebe van Maldegem
Febe van Maldegem
JBJesse Boumelha
Jesse Boumelha
CMChristopher Moore
Christopher Moore
SRSareena Rana
Sareena Rana
JDJulian Downward
Julian Downward
Recently developed KRAS G12C inhibitory drugs are beneficial to lung cancer patients harboring KRAS G12C mutations, but drug resistance frequently develops. Because of the immunosuppressive nature of the signaling network controlled by oncogenic KRAS, these drugs can indirectly affect antitumor immunity, providing a rationale for their combination with immune checkpoint blockade. In this study, we have characterized how KRAS G12C inhibition reverses immunosuppression driven by oncogenic KRAS in a number of preclinical lung cancer models with varying levels of immunogenicity. Mechanistically, KRAS G12C inhibition up-regulates interferon signaling via Myc inhibition, leading to reduced tumor infiltration by immunosuppressive cells, enhanced infiltration and activation of cytotoxic T cells, and increased antigen presentation. However, the combination of KRAS G12C inhibitors with immune checkpoint blockade only provides synergistic benefit in the most immunogenic tumor model. KRAS G12C inhibition fails to sensitize cold tumors to immunotherapy, with implications for the design of clinical trials combining KRAS G12C inhibitors with anti-PD1 drugs.

19 April 2016 in Science Signaling
Verified
Journal Article
Closed access
PDF file
KRKole T. Roybal
Kole T. Roybal
TBTaráz E. Buck
Taráz E. Buck
XRXiongtao Ruan
Xiongtao Ruan
BCBaek Hwan Cho
Baek Hwan Cho
DCDanielle J. Clark
Danielle J. Clark
RMRobert F. Murphy
Robert F. Murphy
Live-cell microscopy determines the relative contributions of different signaling pathways to actin reorganization in T cells.

15 September 2020 in Science Signaling
Verified
Journal Article
Closed access
RARachel Ambler
Rachel Ambler
GEGrace Edmunds
Grace Edmunds
STSin Lih Tan
Sin Lih Tan
SCSilvia Cirillo
Silvia Cirillo
JPJane I. Pernes
Jane I. Pernes
CWChristoph Wulfing
Christoph Wulfing
PD-1 signaling suppresses tumor-infiltrating lymphocytes by destabilizing their interactions with target tumor cells.

31 January 2017 in eLife
Verified
Journal Article
Open access
GBGraham Britton
Graham Britton
RARachel Ambler
Rachel Ambler
DCDanielle J Clark
Danielle J Clark
EHElaine V Hill
Elaine V Hill
HTHelen M Tunbridge
Helen M Tunbridge
DWDavid Wraith
David Wraith
Notch is a critical regulator of T cell differentiation and is activated through proteolytic cleavage in response to ligand engagement. Using murine myelin-reactive CD4 T cells, we demonstrate that proximal T cell signaling modulates Notch activation by a spatiotemporally constrained mechanism. The protein kinase PKCθ is a critical mediator of signaling by the T cell antigen receptor and the principal costimulatory receptor CD28. PKCθ selectively inactivates the negative regulator of F-actin generation, Coronin 1A, at the center of the T cell interface with the antigen presenting cell (APC). This allows for effective generation of the large actin-based lamellum required for recruitment of the Notch-processing membrane metalloproteinase ADAM10. Such enhancement of Notch activation is critical for efficient T cell proliferation and Th17 differentiation. We reveal a novel mechanism that, through modulation of the cytoskeleton, controls Notch activation at the T cell:APC interface thereby linking T cell receptor and Notch signaling pathways.

3 March 2017
Verified
Book Chapter
Closed access
PDF file
RARachel Ambler
Rachel Ambler
XRXiangtao Ruan
Xiangtao Ruan
RMRobert F. Murphy
Robert F. Murphy
CWChristoph Wulfing
Christoph Wulfing